Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates reduced viral titers and mortality with early aerosolized ribavirin in mice, highlighting optimal delivery routes for influenza treatment.
Ribavirin (1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) is an effective antiviral agent against type A influenza infection of mice. Therapy was most effective when administered as a small-particle aerosol early in the infection. Treatment was also effective by either the intraperitoneal or aerosol route in mice with histological evidence of pneumonia. Ribavirin increased the percent survival, lowered lung virus titers, and decreased the development of lung pathology when therapy was initiated at 6 h as a small-particle aerosol. There was no evidence of pulmonary toxicity or immunosuppressive effects.
No takes yet. Share an insight, caveat, or question.
Stephen et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: